Granted Patent
B2
US 12,311,075 · App. 17/567,200 · Granted May 27, 2025
Particles comprising decellularized omentum
Inventors:
Tal Dvir (LeHavim, IL); Assaf Shapira (Moshav Talmei Elazar, IL); Michal Shevach (Tel-Aviv, IL); Idan Gal (Rishon-LeZion, IL)
Assignee:
Ramot at Tel-Aviv University Ltd.
A61L27/3604A61K35/35A61L27/3683A61L27/3687A61L27/3804A61L27/3826A61L27/383A61L27/3834A61L27/54A61L2300/414A61L2400/12A61L2430/40B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A spherical particle comprising decellularized omentum being between 1 nM-300 μM in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.
Claims (13)
1. A composition comprising a plurality of particles fabricated from decellularized omentum, wherein said particles encapsulate biological cells, wherein said particles consist of decellularized omentum and biological cells.
2. The composition of claim 1 , wherein said omentum comprises human omentum.
3. The composition of claim 1 , wherein said biological cells are selected from the group consisting of cardiac cells, neuronal cells, pancreatic cells, stem cells, liver cells, muscle cells, blood cells and immune cells.
4. The composition of claim 1 , wherein each of the particles of said plurality of particles are of substantially the same size.
5. The composition of claim 1 , wherein said biological cells comprise spinal cord motor neurons.
6. The composition of claim 1 , wherein said particles are spherical.
7. A method of treating a disease or medical condition which would benefit from cell transplantation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 1 , thereby treating the medical condition.
8. The method of claim 7 , wherein said decellularized omentum is autologous to the subject.
9. The method of claim 7 , wherein said decellularized omentum is non-autologous to the subject.
10. The method of claim 7 , wherein said biological cells are selected from the group consisting of cardiac cells, neuronal cells, pancreatic cells, stem cells, liver cells, muscle cells, blood cells and immune cells.
11. The method of claim 10 , wherein said biological cells comprise spinal cord motor neurons.
12. The method of claim 10 , further comprising differentiating induced pluripotent stem (iPS) cells of the subject into said cardiac cells, said neuronal cells, said pancreatic cells, said stem cells, said liver cells, said muscle cells, said blood cells or said immune cells prior to said administering.
13. The method of claim 12 , wherein said iPS cells are generated from omentum cells of the subject.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 7, 2022
From: DVIR, TAL; SHAPIRA, ASSAF; SHEVACH, MICHAL; GAL, IDAN
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 058573/0191 →
Continuity (3)
Continuation
16061675
Provisional Application
62268046
· Dec 16, 2015
References Cited (143)
US 5843134A
· Thong et al.
· 1998
[cited by applicant]
US 6600956B2
· Maschino et al.
· 2003
[cited by applicant]
US 20050013870A1
· Freyman et al.
· 2005
[cited by applicant]
US 20070219642A1
· Richter
· 2007
[cited by applicant]
US 20090163990A1
· Yang et al.
· 2009
[cited by applicant]
US 20090238853A1
· Liu
· 2009
[cited by applicant]
US 20100106233A1
· Grant et al.
· 2010
[cited by applicant]
US 20100211172A1
· Bellamkonda et al.
· 2010
[cited by applicant]
US 20100255447A1
· Biris et al.
· 2010
[cited by applicant]
US 20100273667A1
· Kotov et al.
· 2010
[cited by applicant]
US 20110085968A1
· Jin et al.
· 2011
[cited by applicant]
US 20110143429A1
· Chun et al.
· 2011
[cited by applicant]
US 20110306110A1
· Takeuchi et al.
· 2011
[cited by applicant]
US 20120177910A1
· Weber et al.
· 2012
[cited by applicant]
US 20130085359A1
· Yao et al.
· 2013
[cited by applicant]
US 20150202348A1
· Dvir et al.
· 2015
[cited by applicant]
US 20160106886A1
· Dvir et al.
· 2016
[cited by applicant]
US 20180000990A1
· Dvir et al.
· 2018
[cited by applicant]
EP 2229191
· 2012
[cited by applicant]
WO WO2005007233
· 2005
[cited by applicant]
WO WO2009085547
· 2009
[cited by applicant]
WO WO2011154424
· 2011
[cited by applicant]
WO WO2011159923
· 2011
[cited by applicant]
WO WO2012094208
· 2012
[cited by applicant]
WO WO2013040078
· 2013
[cited by applicant]
WO WO2013040087
· 2013
[cited by applicant]
WO WO2013086502
· 2013
[cited by applicant]
WO WO2013109642
· 2013
[cited by applicant]
WO WO2014037942
· 2014
[cited by applicant]
WO WO2014188420
· 2014
[cited by applicant]
WO WO2014207744
· 2014
[cited by applicant]
WO WO2015048136
· 2015
[cited by applicant]
WO WO2015071912
· 2015
[cited by applicant]
WO WO2017103930
· 2017
[cited by applicant]
WO WO2024116183
· 2024
[cited by applicant]
Official Action Dated Jun. 27, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (13 pages).
[cited by applicant]
Advisory Action Dated Jan. 22, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (3 pages).
[cited by applicant]
Brief Communication: Oral Proceedings Dated Jan. 15, 2020 From the European Patent Office Re. Application No. 14862849.8. (9 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jul. 12, 2018 From the European Patent Office Re. Application No. 14741411.4. (6 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Nov. 21, 2019 From the European Patent Office Rc. Application No. 14741411.4. (5 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Sep. 21, 2018 From the European Patent Office Re. Application No. 14862849.8. (7 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 29, 2020 From the European Patent Office Re. Application No. 16875065.1. (8 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Nov. 29, 2018 From the European Patent Office Re. Application No. 14800309.8. (5 Pages).
[cited by applicant]
Final Official Action Dated Oct. 16, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (19 pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Dec. 3, 2015 From the International Bureau of WIPO Re. Application No. PCT/IL2014/050445.
[cited by applicant]
International Preliminary Report on Patentability Dated Jan. 7, 2016 From the International Bureau of WIPO Re. Application No. PCT/IL2014/050568.
[cited by applicant]
International Preliminary Report on Patentability Dated May 26, 2016 From the International Bureau of WIPO Re. Application No. PCT/IL2014/050994.
[cited by applicant]
International Search Report and the Written Opinion Dated Apr. 4, 2017 From the International Searching Authority Re. Application No. PCT/IL2016/051344. (12 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Aug. 18, 2014 From the International Searching Authority Re. Application No. PCT/IL2014/050445.
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 22, 2015 From the International Searching Authority Re. Application No. PCT/IL2014/050994.
[cited by applicant]
International Search Report and the Written Opinion Dated Oct. 24, 2014 From the International Searching Authority Re. Application No. PCT/IL2014/050568.
[cited by applicant]
Notice of Allowance Dated Nov. 8, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (7 pages).
[cited by applicant]
Notice of Allowance Dated Jan. 26, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/037,129. (15 Pages).
[cited by applicant]
Notice of Non-Compliant Amendment (37 CFR 1.121) Dated May 5, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/581,540.
[cited by applicant]
Official Action Dated Jan. 4, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (15 pages).
[cited by applicant]
Official Action Dated Mar. 8, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (16 pages).
[cited by applicant]
Official Action Dated Jan. 10, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/702,834. (19 pages).
[cited by applicant]
Official Action Dated Jun. 11, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 15/037,129. (21 pages).
[cited by applicant]
Official Action Dated Oct. 11, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/037,129. (18 Pages).
[cited by applicant]
Official Action Dated Nov. 12, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (19 Pages).
[cited by applicant]
Official Action Dated Mar. 13, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/581,540. (15 pages).
[cited by applicant]
Official Action Dated May 16, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/702,834. (17 Pages).
[cited by applicant]
Official Action Dated Mar. 21, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/037,129. (38 pages).
[cited by applicant]
Official Action Dated Sep. 21, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (29 pages).
[cited by applicant]
Official Action Dated May 22, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (32 pages).
[cited by applicant]
Official Action Dated Dec. 27, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (32 pages).
[cited by applicant]
Official Action Dated Jun. 28, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/581,540.
[cited by applicant]
Official Action Dated Jun. 30, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (10 Pages).
[cited by applicant]
Restriction Official Action Dated Dec. 13, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/061,675. (7 pages).
[cited by applicant]
Restriction Official Action Dated Jul. 13, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/891,375. (9 pages).
[cited by applicant]
Restriction Official Action Dated Nov. 26, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/702,834. (9 Pages).
[cited by applicant]
Restriction Official Action Dated Mar. 31, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/581,540.
[cited by applicant]
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Jul. 17, 2019 From the European Patent Office Re. Application No. 14862849.8. (8 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jul. 22, 2019 From the European Patent Office Re. Application No. 16875065.1. (8 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jun. 22, 2017 From the European Patent Office Re. Application No. 14862849.8. (12 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Nov. 28, 2016 From the European Patent Office Re. Application No. 14800309.8. (7 Pages).
[cited by applicant]
Achyuta ct al. “Biocompatibility Assessment of Insulating Silicone Polymer Coatings Using an in vitro Glial Scar Assay”, Macromolecular Bioscience 10: 872-880, 2010.
[cited by applicant]
Aregueta-Robles et al. “Organic Electrode Coatings for Next-Generation Neural Interfaces”, Frontiers in Neuroengineering, 7(Art. 15): 1-7, May 27, 2014. Abstract, Fig.1.
[cited by applicant]
Broda et al. “A Chemically Polymerized Electrically Conducting Composite of Polypyrrole Nanoparticles and Polyurethane for Tissue Engineering”, Journal of Biomedical Materials Research, 98(4): 509-516, Sep. 15, 2011.
[cited by applicant]
Cohen-Karni et al. “Nanocomposite Gold-Silk Nanofibers”, Nano Letters, 12(10): 5403-5406, Aug. 28, 2012.
[cited by applicant]
Cohen-Karni et al. “Nanocomposite Gold-Silk Nanofibers”, Nano Letters, 12(10): 5403-5406, Aug. 28, 2012. Fig. 1B.
[cited by applicant]
Collins et al. “The Poisson Distribution and Beyond: Methods for Microfluidic Droplet Production and Single Cell Encapsulation”, Lab on A Chip, XP055426432, 15(17): 3439-3459, Published Online Jul. 30, 2015.
[cited by applicant]
Crapo et al. “An Overview of Tissue and Whole Organ Decellularization Processes”, Biomaterials, 32(12): 3233-3243, Apr. 30, 2011.
[cited by applicant]
Dvir et al. “Activation of the ERK1/2 Cascade Via Pulsatile Interstitial Fluid Flow Promotes Cardiac Tissue Assembly”, Tissue Engineering, 13(9): 2185-2193, Sep. 2007.
[cited by applicant]
Dvir et al. “Nanowired Three-Dimensional Cardiac Patches”, Nature Nanotechnology, XP055526382, 6(11): 720-725, Published Online Sep. 25, 2011.
[cited by applicant]
Dvir et al. “Precascularization of Cardiac Patch on the Omentum Improves Its Therapeutic Outcome”, Proc. Natl. Acad. Sci. USA, PNAS, 106(35): 14990-14995, Sep. 1, 2009.
[cited by applicant]
Engelmayr Jr. et al. “Accordion-Like Honeycombs for Tissue Engineering of Cardiac Anisotropy”, Nature Materials, 7(12): 1003-1010, Dec. 2008.
[cited by applicant]
Fleischer et al. “Albumin Fiber Scaffolds for Engineering Functional Cardiac Tissues”, Biotechnology and Bioengineering, 111(6): 1246-1257, Jun. 2014.
[cited by applicant]
Fleischer et al. “Coiled Fiber Scaffolds Embedded With Gold Nanoparticles Improve the Performance of Engineered Cardiac Tissues”, Nanoscale, 6(16): 9410-9414, Aug. 21, 2014.
[cited by applicant]
Fleischer et al. “Spring-Like Fibers for Cardiac Tissue Engineering”, Biomaterials, 34(34): 8599-8606, Available Online Aug. 13, 2013.
[cited by applicant]
Gilbert et al. “Decellularization of Tissues and Organs”, Biomaterials, XP002730648, 27(19): 3675-3683, Jul. 2006. p. 3676, Para 2, Table 1, p. 3679, Para 3.
[cited by applicant]
Homola “Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species”, Chemical Reviews, 108(2): 462-493, Jan. 30, 2008.
[cited by applicant]
Hsu et al. “Gold Nanoparticles Induce Surface Morphological Transformation in Polyurethane and Affect the Cellular Response”, Biomacromolecules, 9(1): 241-248, Jan. 2008.
[cited by applicant]
Johnson et al. “Tailoring Material Properties of A Nanofibrous Extracellular Matrix Derived Hydrogel”, Nanotechnology, 22(49): 494015-1-494015-23, Published Online Nov. 21, 2011.
[cited by applicant]
Mao et al. “Recent Advances in Polymeric Microspheres for Parental Drug Delivery—Part 2”, Expert Opinion on Drug Delivery, XP055605149, 9(10): 1209-1223, Aug. 28, 2012.
[cited by applicant]
Merriam-Webster “Particle” Definition, Retrieved from www.merriam-webster.com, 1 Page, 2019.
[cited by applicant]
Porzionato et al. “Decellularization of Rat and Human Omentum to Develop Novel Scaffolds to Be Recellularized With Adipose Derived Stem Cells”, Italian Journal of Anatomy and Embryology, IJAE, 116(1/Suppl.): 149, 2011.
[cited by applicant]
Porzionato et al. “Decellularized Omentum as Novel Biologic Scaffold for Reconstructive Surgery and Regenerative Medicine”, European Journal of Histpchemistry, 57(e4): 24-30, 2013.
[cited by applicant]
Prabhakaran et al. “Electrospun Composite Scaffolds Containing Poly(Octanediol-CO-Citrate) for Cardiac Tissue Engineering”, Biopolymers, 97(7): 529-538, Feb. 10, 2012.
[cited by applicant]
Prabhakaran et al. “Electrospun Composite Scaffolds Containing Poly(Octanediol-CO-Citrate) for Cardiac Tissue Engineering”, Biopolymers, 97(7): 529-538, Published Online Feb. 10, 2012.
[cited by applicant]
Radisic et al. “Functional Assembly of Engineered Myocardium by Electrical Stimulation of Cardiac Myocytes Cultured on Scaffolds”, Proc. Natl. Acad. Sci. USA, PNAS, 101(52): 18129-18134, Dec. 28, 2004.
[cited by applicant]
Sawkins et al. “Hydrogels Derived From Demineralized and Decellularized Bone Extracellular Matrix”, Acta Biomaterialia, 9: 7865-7873, 2013.
[cited by applicant]
Sawkins et al. “Hydrogels Derived From Demineralized and Decellularized Bone Extracellular Matrix”, Acta Biomaterialia, XP002730649, 9(8): 7865-7873, Available Online Apr. 25, 2013. p. 7866, 1-h col. Para 2, r-h col., P…
[cited by applicant]
Shevach et al. “Fabrication of Omentum-Based Matrix for Engineering Vascularized Cardiac Tissues”, Biofabrication, 6(2): 024101-1-024101-12, Published Online Jan. 24, 2014. Para 4.1, p. 9, Fig.8.
[cited by applicant]
Shevach et al. “Gold Nanoparticle-Decellularized Matrix Hybrids for Cardiac Tissue Engineering”, Nano Letters, 14(10): 5792-5796, Sep. 8, 2014.
[cited by applicant]
Shevach et al. “Nanoengineering Gold Particle Composite Fibers for Cardiac Tissue Engineering”, Journal of Materials Chemistry B, 1(39): 5110-5217, 2013.
[cited by applicant]
Shevach et al. “Omentum ECM-Based Hydrogel as A Platform for Cardiac Cell Delivery”, Biomedical Materials, 10(3): 034106-1-034106-11, May 13, 2015. Para 2.1, p. 2, Fig.7.
[cited by applicant]
Singelyn et al. “Catheter-Deliverable Hydrogel Derived From Decellularized Ventricular Extracellular Matrix Increases Endogenous Cardiomyocytes and Preserves Cardiac Function Post-Myocardial Infarction”, Journal of the …
[cited by applicant]
Soffer-Tzur et al. “Optimizing the Biofabrication Process of Omentum-Based Scaffolds for Engineering Autologous Tissues”, Biofabrication, 6(3): 035023-1-035023-14, Published Online Aug. 27, 2014. Table 1.
[cited by applicant]
Tian et al. “Macroporous Nanowire Nanoelectronic Scaffolds for Synthetic Tissues”, Nature Materials, 11: 986-994, Nov. 2012 & Supplementary Information, p. 1-27, 2012.
[cited by applicant]
Whelove et al. “Development and In Vitro Studies of A Polyethylene Terephthalate- Gold Nanoparticle Scaffold for Improved Biocompatibility”, Journal of Biomedical Materials Research, Part B: Applied Biomaterials, 99B(1)…
[cited by applicant]
Whelove et al. “Development and In Vitro Studies of A Polyethylene Terephthalate-Gold Nanoparticle Scaffold for Improved Biocompatibility”, Journal of Biomedical Materials Rescarch, Part B: Applied Biomaterials, 99B(1):…
[cited by applicant]
Yao et al. “Collagen Microsphere Serving as A Cell Carrier Supports Oligodendrocyte Progenitor Cell Growth and Differentiation for Neurite Myelination In Vivo”, Stem Cell Research & Therapy, XP021162904, 4(5): 109-1-109…
[cited by applicant]
You et al. “Nanoengineering the Heart: Conductive Scaffolds Enhance Connexin 43 Expression”, Nano Letters, 11(9): 3643-3648, Aug. 1, 2011.
[cited by applicant]
You et al. “Nanoengineering the Heart: Conductive Scaffolds Enhance Connexin 43 Expression”, Nano Letters, XP055204904, 11(9): 3643-3648, Aug. 1, 2011.
[cited by applicant]
Zhang et al. “Neurite Development in PC12 Cells on Nanostructured Substrates”, Advances in Science and Technology, 53: 85-90, Oct. 1, 2006.
[cited by applicant]
Zimmermann et al. “Tissue Engineered of A Differential Cardiac Muscle Construct”, Circulation Research, 90(2): 223-230, Feb. 8, 2002.
[cited by applicant]
Official Action Dated Jul. 1, 2024 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (15 Pages).
[cited by applicant]
Official Action Dated May 12, 2022 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (40 pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 7, 2024 From the International Searching Authority Re. Application No. PCT/IL2023/051227 (12 Pages).
[cited by applicant]
Final Official Action Dated Nov. 28, 2022 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (11 pages).
[cited by applicant]
Advisory Action Dated Feb. 1, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (3 pages).
[cited by applicant]
Official Action Dated Dec. 7, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (19 pages).
[cited by applicant]
Pati et al. “Printing Three-Dimensional Tissue Analogues with Decellularized Extracellular Matrix Bioink”, Nature Communications, 5:3935, pp. 1-11, Jun. 2, 2024.
[cited by applicant]
Official Action Dated Dec. 9, 2024 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/686,158. (24 Pages).
[cited by applicant]